Research programme: human blood coagulation factors - Glycotope/ Octapharma

Drug Profile

Research programme: human blood coagulation factors - Glycotope/ Octapharma

Alternative Names: FVII-GEX

Latest Information Update: 30 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Glycotope
  • Developer Glycotope; Octapharma
  • Class Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIII stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 30 Nov 2015 Glycotope and Octapharma agree to co-develop human blood coagulation factors in Germany and Switzerland for Coagulation disorders
  • 08 Oct 2015 Preclinical trials in Haemophilia in Germany (unspecified route)
  • 08 Oct 2015 Preclinical trials in Haemophilia in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top